RxDoctor Payments Data

Joseph Cabaret, MD

Interventional Pain Medicine · Camarillo, CANPI 1689600041

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,539 of the $7,276 with a category attached, or 89.9%. 33 manufacturers reported payments, led by Medtronic at 46.9% of the total. Reporting peaked in 2023 at $1,801 and has fallen 76.9% since, to $416 in 2025.

$7,276in general payments, 2019–2025

Across 188 payments — averaging $38.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Relievant Medsystems, Inc.$748
  • AbbVie$457
  • Neuronetics, Inc.$318
  • Boston Scientific$240
  • Nevro Corp.$226
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$3104%
  • Travel & lodging$4276%
  • Food & beverage$6,53990%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,276 in reported general payments places this provider in the 70th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$181,190
Medicare patients
234
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine19$4,813
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$2,755
Gabapentin49$529
Duloxetine Hcl59$480
Pregabalin14$329
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$223
Meloxicam12$66

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Camarillo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →